AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00778596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Study NCT00778596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo priming
Description: Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
Study NCT02559037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion
Description: Acupuncture acupoints: CV12, bilateral ST36, ST37, SP6, SP9, SP4, LR3 and LI3. Disposable acupuncture auxiliary device and 0.30\*40mm or 0.30\*25mm acupuncture needles (hwato, suzhou medical supplies factory co., LTD.) were used. The needles were directly inserted 20-30mm into the skin and elicited a de-qi sensation. The needle was kept for 30 min.~Moxibustion acupoints: bilateral ST25 and ST36. Using mild-warm moxibustion, The surface temperature of acupoints were maintained at 43 ℃ ± 1 ℃, 30min for each acupoint. Moxibustion and acupuncture were performed at the same time, once every other day, three times a week, a total of 12 weeks of treatment. After the treatment, subjects were followed up in the weeks 24, 36 and 48.
Study NCT02559037 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture and moxibustion
Description: The acupoints used are same to the experimental group. Same disposable acupuncture auxiliary device and 0.35 \* 40mm acupuncture needle (flat and blunt needle tip, Hwato, Suzhou Medical Supplies Factory Co., Ltd.) was selected. When the needle was pricked to the acupoint, it did not penetrating into the skin. The subject only felt slight pain and do not have the de-qi sensation.~Sham moxibustion : by using the same moxa stick, The surface temperature of acupoints were maintained at 37 ℃ ± 1 ℃, 30min for each acupoint. Sham acupuncture and sham moxibustion were performed at the same time. They were treated once every other day, three times a week, a total of 12 weeks. After the treatment, subjects were followed up in the weeks 24, 36 and 48.
Study NCT04268407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: compare the duration of antbiotic use: 2 day versus 7 day
Study NCT04268407 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin Clavulanate
Description: compare the duration of antbiotic use: 2 day versus 7 day
Study NCT02118103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Lumbar spinal manipulation
Study NCT04383301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorneal ring segment implantaion as the first stage
Description: Intracorneal ring segment (ICRS)
Study NCT04383301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACXL and wafe front guieded TPRK as the second stage
Description: Accelerated corneal cross linking (ACXL) and wafe front guided transepithelial photorefractive keratotomy (TPRK)
Study NCT01276158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound used to place arterial line
Study NCT01276158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Doppler
Description: Doppler used to place arterial line
Study NCT01455870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 mcg/day
Description: exenatide in DUROS
Study NCT01455870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: oral sitagliptin 100 mg/day
Study NCT01086670 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical Exercise
Description: Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or over-training effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions. Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses.
Study NCT01897337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
Study NCT01897337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
Study NCT00956839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol)
Description: Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months
Study NCT01053156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: minocycline hydrochloride
Description: Minocycline hydrochloride dosed orally once a day for 3 months.
Study NCT01053156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given daily for 3 months.
Study NCT01988467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to second hand smoking
Description: The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
Study NCT04670289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT03714087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T1 before aligner
Description: The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
Study NCT03714087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T2 after the aligner
Description: The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
Study NCT03714087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Historic control group
Study NCT02642263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Postpartum uterotonic drug
Study NCT00230880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: follow-up phone counseling
Description: 9 calls over 12 months
Study NCT02296723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg
Study NCT02296723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir Hydrochloride
Description: Valganciclovir Hydrochloride Tablets 450 mg
Study NCT00231452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
Description: Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
Study NCT00231452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)
Description: Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
Study NCT02104778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
Study NCT02104778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
Study NCT03814148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LENINGRADO 5 association
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natrilix® SR
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natrilix SR Placebo
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT03814148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leningrado 5 association Placebo
Description: 1 coated sustained-release tablet, oral, once a day.
Study NCT00684723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg Tablets
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Study NCT00684723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin (Mevacor®) 40 mg Tablets
Description: 40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
Study NCT03013075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with Bupivacaine heavy and Morphine
Description: Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
Study NCT03013075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine heavy and Morphine
Study NCT03013075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthetics
Study NCT03013075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthetics
Study NCT00697645 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep TMS (Transcranial magnetic stimulation)
Description: All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
Study NCT00697645 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Brainsway Deep TMS
Description: Deep TMS applied over the motor strip
Study NCT00697645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsway Deep TMS
Description: Deep TMS applied over the motor strip
Study NCT03746587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arimoclomol
Description: Arimoclomol in 3 different dosages
Study NCT03746587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsule
Study NCT03227406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Subjects are kept awake all night.
Study NCT03227406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Participants are given a 90-minute nap opportunity in the early afternoon.
Study NCT02179125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RePneu Lung Volume Reduction Coil System
Description: Bronchoscopic lung volume reduction treatment with Coils.
Study NCT01614301 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus
Description: Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity
Study NCT01614301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus
Description: Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity
Study NCT03812302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68-Ga HA-DOTATATE PET/CT
Description: See arm description.
Study NCT02063373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
Study NCT03089138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regan Tangjiang
Description: The treatment duration is 3 consecutive days.
Study NCT03089138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regan Tangjiang
Description: The treatment duration is 3 consecutive days.
Study NCT03089138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regan Tangjiang
Description: The treatment duration is 3 consecutive days.
Study NCT06266624 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tourniquet Test
Description: Tourniquet Test was performed in patients with HHT
Study NCT00667147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Weekly Abraxane and Daily Vandetanib
Description: Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
Study NCT00667147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane every three weeks and daily vandetanib
Description: Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
Study NCT03814551 — intervention group
Intervention type: BEHAVIORAL
Intervention: Signage
Description: Placement of signage discouraging consumption of beverages with added sugar
Study NCT04341467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: The initial dose of amisulpride group is 50mg/d, and the maximum dose is 800mg/d.
Study NCT04341467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: The initial dose of olanzapine is 2.5 mg/d, and the maximum dose is 20 mg/d.
Study NCT03378453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-scan18F-AV-45
Description: The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr
Study NCT03378453 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-scan18F-AV-45
Description: PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
Study NCT02299414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-hypertensive therapy
Description: 1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
Study NCT02299414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No anti-hypertensive therapy (unless BP is severe)
Description: Treatment will not be started if blood pressure remains \<160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
Study NCT03154970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Craniocervical flexion training
Description: The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
Study NCT02776995 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thermography imaging
Description: Thermography imaging of the treated - irradiated body area.
Study NCT05195021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EDDY
Description: EDDY (VDW) sonic irrigation activation system
Study NCT05195021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser device
Description: 980-nm diode laser device
Study NCT05195021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional irrigation
Description: Conventional root canal irrigation with 31-guage side port needle
Study NCT03143257 — intervention group
Intervention type: DEVICE
Intervention: Sophono Bone Conduction Hearing Systems
Description: The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of Bone Conduction (BC) of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear.
Study NCT01307787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental Fit-program
Description: Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
Study NCT01307787 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: waiting list control group with no intervention
Study NCT01357291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recidivism Reduction Program
Description: Assigned to the 21-module Recidivism Reduction Program
Study NCT01357291 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Business-as-usual
Description: Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
Study NCT02627404 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: A blood sample is taken at inclusion of patients in the study to perform DNA analysis
Study NCT02627404 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: actometer
Description: To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
Study NCT00477763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis, Refresh Endura
Description: 1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
Study NCT00477763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Restasis, Refresh Endura
Description: 1. Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~2. Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
Study NCT01996371 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pedicle Screw
Study NCT01914393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Description: Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
Study NCT03457389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabergoline
Description: Cabergoline tablet
Study NCT03457389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Cabergoline tablet